Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®

RegulatoryapprovedLeqembiPositive

AI Analysis

Summary

Canada's Drug Agency issued a final positive recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients with mild cognitive impairment. This regulatory approval is a significant milestone for Eisai and its partner BioArctic AB in expanding access to the treatment in Canada.

Outcome Details

Canada's Drug Agency issued final positive recommendation supporting public reimbursement of Leqembi for eligible patients with mild cognitive impairment

Importance:7/10

Sentiment:

0.85

regulatory approvalreimbursementCanadaAlzheimer's diseaseBioArcticEisai

Related Companies

$BIOA-B.ST $ESALY

Read the original article

Published by PR Newswire Pharma on September 1, 2026 5:25 AM

Read Original